ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 2, 2018
In the News: Gold, Auto Sales, General Electric
We don’t think gold makes much sense outside perhaps a very diversified portfolio. Auto sales weren’t all that great in September, and some are calling for a bottom in General Electric.
Aug 31, 2018
Stellar Keytruda Growth Powers Merck Higher
Shares of pharmaceutical giant Merck continue to accelerate thanks in large part to the growth of its key oncology asset Keytruda. Even though Merck is a well-established entity, future growth is highly correlated to the continued expansion of Keytruda as it continues to gain market share thanks in large part to superior clinical data and label expansion.
Aug 31, 2018
Dividend Increases/Decreases for the Week Ending August 31
Let's take a look at companies that raised/lowered their dividend this week.
Aug 13, 2018
The Berkshire Breakout
Image shown: Berkshire Hathaway's shares have broken out following the release of its second-quarter 2018 results. We continue to believe Berkshire Hathaway belongs in the simulated Best Ideas Newsletter portfolio. Warren Buffett and Charlie Munger have more flexibility to pursue share buybacks, and we’d be flat-out surprised if Berkshire were to buy Southwest outright. Berkshire’s cash balance continues to grow, and we think a stake in Facebook might be the best opportunity for a part of the equity security allocation.
Aug 1, 2018
Johnson & Johnson: Headline Risk But Business Solid
We remain big fans of the steady hand displayed by the venerable Johnson & Johnson as the pharmaceutical bellwether continues to perform admirably. During its second-quarter results, we came away impressed with the continued strength in the Oncology division, which masks the deceleration in growth in Cardiovascular Disease. There continues to be headline risk with respect to talcum powder litigation, but J&J’s underlying business remains solid, in our view.
Jul 11, 2018
In the News: More Tariff Talk Keeps Markets Volatile
Many market observers were caught by surprise after President Trump continued down a path of escalating trade tensions late July 10.
Jun 1, 2018
Dividend Increases/Decreases for the Week Ending June 1
Let's take a look at companies that raised/lowered their dividend this week.
May 2, 2018
Optimizing Coverage
We're shifting our coverage around a bit to better allocate resources to areas that are of interest to you!
Apr 30, 2018
Portfolio Diversification Begins at Alexion; Shares Cheap
Image Source: Alexion. We view the acquisition of differentiated, late-stage molecules at an attractive rate as the optimal use of free cash flow for many in the biotech industry. The finite commercial life of a patented drug forces continued innovation as near-total revenue erosion is a certainty once patent protection has lapsed. Let’s review some of the recent events at Alexion to gain a further understanding of the underlying trends affecting the business.
Apr 25, 2018
Demand Bouncing Off Multi-Year Bottom at Caterpillar
Improvement in Caterpillar’s underlying end markets is driving its performance, and management took the opportunity following a solid showing in the first quarter of 2018 to raise its bottom-line guidance for the full year. The market, however, did not look favorably on management’s comments that the first quarter should be expected to be the “high-water mark” for the year in terms of margin performance. We’ve updated our fair value estimate of shares.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.